Investments
6Portfolio Exits
1About Piedmont Capital Partners
Piedmont Capital Partners is a Merchant Banking firm, located in Glen Allen, Virginia. The firm was created in 2005 with the goal of drawing on the prior 20 plus years of merchant banking, corporate development, investment and finance experience of the firm's Managing Partner, Stan Manoogian.
Piedmont Capital Partners Headquarter Location
United States
Latest Piedmont Capital Partners News
Nov 13, 2018
AsclepiX Therapeutics, Inc. , a Baltimore, MD-based biopharmaceutical company focused on developing vital new therapies based on a novel peptide platform, raised $5m in convertible note funding. The round was led by Barer & Son Capital with participation from Rapha Capital Management, Salem Partners, TEDCO, and Piedmont Capital Partners. In conjunction with the funding, AsclepiX expanded its board to add Josh Barer, Kevin Slawin, MD, and Sapna Srivastava, PhD, to the founding members Aleksander Popel, PhD and Jordan J. The company intends to use the funds to accelerate development of AXT107, its innovative treatment for two leading causes of adult blindness: – diabetic macular edema (DME) and – wet age-related macular degeneration (wet AMD). Led by CEO Perrow, AsclepiX Therapeutics is advancing a treatment of ocular diseases and cancer focusing on a novel peptide platform which inhibits and potentially reverse disease progression. The mechanism of action of AXT107 targets multiple pathways, including vascular endothelial growth factor A (VEGF-A) and Tie2, two factors that promote formation of blood vessels and leakage of fluid in the diseased retina. The company is initially focused on ocular diseases currently treated with anti-VEGF monotherapies. FinSMEs 13/11/2018
Piedmont Capital Partners Investments
6 Investments
Piedmont Capital Partners has made 6 investments. Their latest investment was in Posh as part of their Series A on December 12, 2021.
Piedmont Capital Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
12/9/2021 | Series A | Posh | $27.5M | Yes | 14 | |
10/13/2020 | Series B | |||||
11/13/2018 | Convertible Note | |||||
1/2/2018 | Series A | |||||
6/1/2017 | Series B |
Date | 12/9/2021 | 10/13/2020 | 11/13/2018 | 1/2/2018 | 6/1/2017 |
---|---|---|---|---|---|
Round | Series A | Series B | Convertible Note | Series A | Series B |
Company | Posh | ||||
Amount | $27.5M | ||||
New? | Yes | ||||
Co-Investors | |||||
Sources | 14 |
Piedmont Capital Partners Portfolio Exits
1 Portfolio Exit
Piedmont Capital Partners has 1 portfolio exit. Their latest portfolio exit was NexImmune on February 12, 2021.
Piedmont Capital Partners Team
1 Team Member
Piedmont Capital Partners has 1 team member, including current Founder, Managing Partner, Louise Freemon Brady.
Name | Work History | Title | Status |
---|---|---|---|
Louise Freemon Brady | Founder, Managing Partner | Current |
Name | Louise Freemon Brady |
---|---|
Work History | |
Title | Founder, Managing Partner |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.